Adaptive Dunnett Tests for Treatment Selection
|
|
- Vincent Leonard
- 6 years ago
- Views:
Transcription
1 s for Treatment Selection Franz König 1 Werner Brannath 1 Frank Bretz 2 Martin Posch 1 1 Section of Medical Statistics Medical University of Vienna 2 Novartis Pharma AG Basel Workshop Adaptive Designs 2006 Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs 06 1 / 18
2 Motivation Flexible vs Classical frequentist designs Flexible (Adaptive) Versus Frequentist Trial Classical frequentist trials details of design and analysis must be prefixed in advance (population, treatments, doses, main and secondary outcome variable(s), analysis strategy, sample sizes,...) lack of flexibility to react to information from inside or outside the trial Flexible (adaptive) design allow for mid-trial design modifications based on all internal and external information gathered at interim analyses without compromising the type I error rate To control the type I error rate, the design modifications need not be specified in advance. Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs 06 2 / 18
3 Seamless Designs Drug Development Flexible Trials and Drug Development Full flexibility (unscheduled adaptivity)= adapting design parameters without a (complete) specification of the adaptation rule. dealing with the unexpected dealing with the expected unpredictability of clinical trials Flexible designs allow to... integrate Phase II and Phase III trials into a single trial (adaptive seamless designs, e.g., Bauer & Kieser 1999, Bretz et al 2006,...) formally integrate the data of exploratory and confirmatory phases speed up the drug development process react flexibly to unexpected events Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs 06 3 / 18
4 Seamless Designs Treatment selection Flexible Trial with Treatment Selection (Phase II + III) Comparison of k treatments with a control. Treatments are selected during the trial. Selection rule need not be laid down in detail in advance. Scientific expert knowledge not known at the planning stage will influence the decision process. Selection rule is complex and unknown at planning stage. Treatment selection may be based on un-blinded interim data on the primary efficacy endpoint, secondary and safety endpoints, external information. Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs 06 4 / 18
5 Seamless Designs Treatment selection Flexible Trial with Treatment Selection (Phase II + III) Comparison of k treatments with a control. Treatments are selected during the trial. Selection rule can not? be laid down in detail in advance. Scientific expert knowledge not known at the planning stage will influence the decision process. Selection rule is complex and unknown at planning stage. Treatment selection may be based on un-blinded interim data on the primary efficacy endpoint, secondary and safety endpoints, external information. Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs 06 4 / 18
6 Seamless Designs Multiple type I error Treatment Selection & Multiple Testing Identify effective treatments while controlling the multiple type I error rate in the strong sense: Multiple type I error rate: The probability that at least one ineffective treatment is declared effective is controlled regardless of the number of (non-)effective treatments. Multiple testing procedures: Bonferroni, Dunnett... Test Designs with Treatment Selection Group Sequential Tests (Jennison & Turnbull, 2000) Tests with predefined selection rules (Thall et al. 1988, 1989, Stallard & Todd 2003) Combination Tests combined with the closed testing principle (Kieser et al. 1999, Bauer & Kieser 1999, Hommel 2001, Hommel & Kropf 2001,...) Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs 06 5 / 18
7 Seamless Designs Setup The Testing Problem Parallel group design with k = 2 treatments T 1 and T 2 and a control group T 0. Normal responses with common (known) variance (σ = 1). Testing the one sided hypotheses for the means at multiple level α = H 0,1 : µ 1 µ 0 = 0 vs H 1,1 : µ 1 µ 0 > 0 H 0,2 : µ 2 µ 0 = 0 vs H 1,2 : µ 2 µ 0 > 0 Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs 06 6 / 18
8 Classical Dunnett Test Treatment selection Treatment Selection with the Classical Dunnett Test Start with a classical step down Dunnett test to compare k treatments with a control. In (possibly unplanned) interim analyses treatments may be dropped based on all internal or external information. In the final analysis apply the critical boundaries of the original Dunnet test (correcting for k comparisons) to the remaining treatment control comparisons. Remarks Very Simple Approach No other adaptations (e.g. sample size reassessment) are possible The procedure is strictly conservative Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs 06 7 / 18
9 Classical Dunnett Test Closure Principle and the Dunnett Test The Closed Testing Principle with Dunnett Tests Dunnett test ϕ 12 at level α for H 0,1 H 0,2 max(z 1, Z 2) d2 YES NO H 0,1 and H 0,2 are accepted. Test ϕ 1 at level α for Test ϕ 2 at level α for Z H 0,1 H 0,2 1 d1 Z2 d1 Z i... z-score for treatment-control comparison of T i (i = 1, 2) d j... (Dunnett) critical boundary correcting for j comparisons.. Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs 06 8 / 18
10 Classical Dunnett Test Closure Principle and the Dunnett Test The Closed Testing Principle with Dunnett Tests Dunnett test ϕ 12 at level α for H 0,1 H 0,2 max(z 1, Z 2) d2 Test ϕ 1 at level α for Test ϕ 2 at level α for H 0,1 Z1 d1 H 0,2 Z2 d1 Z i... z-score for treatment-control comparison of T i (i = 1, 2) d j... (Dunnett) critical boundary correcting for j comparisons.. Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs 06 8 / 18
11 Classical Dunnett Test Closure Principle and the Dunnett Test The Closed Testing Principle with Dunnett Tests Dunnett test ϕ 12 at level α for H 0,1 H 0,2 max(z 1, Z 2) d2??? Test ϕ 1 at level α for Test ϕ 2 at level α for H 0,1 Z1 d1 H 0,2 Z2 d1 Z i... z-score for treatment-control comparison of T i (i = 1, 2) d j... (Dunnett) critical boundary correcting for j comparisons.. Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs 06 8 / 18
12 Classical Dunnett Test Closure Principle and the Dunnett Test The Closed Testing Principle with Dunnett Tests Dunnett test ϕ 12 at level α for H 0,1 H 0,2 max(z 1, Z 2 = ) d2!!! Test ϕ 1 at level α for Test ϕ 2 at level α for H 0,1 Z1 d1 H 0,2 Z2 d1 Z i... z-score for treatment-control comparison of T i (i = 1, 2) d j... (Dunnett) critical boundary correcting for j comparisons Note that d 2 > d 1. This is a strictly conservative test if only one treatment is selected! Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs 06 8 / 18
13 Procedure Treatment Selection with the Adaptive Dunnett Test Start with a classical step down Dunnett test to compare k treatments with a control. In (possibly unplanned) interim analyses treatments may be dropped based on all internal or external information. In the final analysis apply the closure principle with conditional error rates of Dunnett tests for the intersection hypotheses. Remarks The procedure controls the multiple level. Improves the Classical Dunnett test uniformly in the case of treatment selection. Further adaptations are possible Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs 06 9 / 18
14 Procedure Treatment Selection with the Adaptive Dunnett Test Start with a classical step down Dunnett test to compare k treatments with a control. In (possibly unplanned) interim analyses treatments may be dropped based on all internal or external information. In the final analysis apply the closure principle with conditional error rates of Dunnett tests for the intersection hypotheses. Remarks The procedure controls the multiple level. Improves the Classical Dunnett test uniformly in the case of treatment selection. Further adaptations are possible Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs 06 9 / 18
15 Conditional Error The Conditional Error Rate Principle Consider a test ϕ to test a hypothesis H 0. The conditional error rate principle (Müller & Schäfer 2001) At an interim analysis we compute: A(interim data) = P H0 ( ϕ rejects H0 interim data ) Continue with an independent second stage and a test for H 0 at level A(interim data). In the final analysis reject H 0 iff q A(interim data), where q is the p-value from the second stage data The resulting procedure controls the level α. Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18
16 Closure principle and the conditional error The Adaptive Dunnett Test The Closed Testing Principle and Conditional Error Dunnett test ϕ 12 at level α for H 0,1 H 0,2 Test ϕ 1 at level α H 0,1 Test ϕ 2 at level α H 0,2 After selecting treatment T 1 only: reject H 0,1 iff q 1 min{a 12, A 1 } Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18
17 Closure principle and the conditional error The Adaptive Dunnett Test The Closed Testing Principle and Conditional Error Dunnett test ϕ 12 at level α for H 0,1 H 0,2 max(z 1, Z 2) d2 Test ϕ 1 at level α Test ϕ 2 at level α H 0,1 H 0,2 Z1 d1 Z2 d1 After selecting treatment T 1 only: reject H 0,1 iff q 1 min{a 12, A 1 } Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18
18 Closure principle and the conditional error The Adaptive Dunnett Test The Closed Testing Principle and Conditional Error Dunnett test ϕ 12 at level α for H 0,1 H 0,2 q12 A 12(interim data T 0,T 1 & T 2) Test ϕ 1 at level α Test ϕ 2 at level α H 0,1 H 0, q1 A 1(interim data T 0,T 1) q A (interim data T,T ) After selecting treatment T 1 only: reject H 0,1 iff q 1 min{a 12, A 1 } Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18
19 Closure principle and the conditional error The Adaptive Dunnett Test Selecting only Treatment 1 Dunnett test ϕ 12 at level α for H 0,1 H 0,2 q 1 A 12(interim data T 0,T1 &T 2) Test ϕ 1 at level α H 0,1 q1 A 1(interim data T 0,T 1) Test ϕ 2 at level α H 0,2 q2 A 2(interim data T 0,T 2) After selecting treatment T 1 only: reject H 0,1 iff q 1 min{a 12, A 1 } Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18
20 Uniform Improvement: Conditional Error Uniform improvement after selecting only T 1 Adaptive Dunnett Test A 12 = P H0 (max(z 1, Z 2 ) d 2 i.d.) A 1 = P H0 (Z 1 d 1 interim data) Reject H 0,1 iff q 1 min{a 12, A 1 } Classical Dunnett Test A 12 := P H 0 (Z 1 d 2 interim data) Rejects H 0,1 iff q 1 A 12 A 12 > A 12 A 1 > A 12 (since d 1 < d 2 ) min{a 12, A 1 } > A 12 for all interim data (i.d.) of T 0, T 1, T 2. The adaptive Dunnett test may borrow strength from the dropped treatments to test the intersection hypotheses. Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18
21 Uniform Improvement: Conditional Error Uniform improvement after selecting only T 1 Adaptive Dunnett Test A 12 = P H0 (max(z 1, Z 2 ) d 2 i.d.) A 1 = P H0 (Z 1 d 1 interim data) Reject H 0,1 iff q 1 min{a 12, A 1 } Classical Dunnett Test A 12 := P H 0 (Z 1 d 2 interim data) Rejects H 0,1 iff q 1 A 12 A 12 > A 12 A 1 > A 12 (since d 1 < d 2 ) min{a 12, A 1 } > A 12 for all interim data (i.d.) of T 0, T 1, T 2. The adaptive Dunnett test may borrow strength from the dropped treatments to test the intersection hypotheses. Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18
22 Uniform Improvement: Conditional Error Uniform improvement after selecting only T 1 Adaptive Dunnett Test A 12 = P H0 (max(z 1, Z 2 ) d 2 i.d.) A 1 = P H0 (Z 1 d 1 interim data) Reject H 0,1 iff q 1 min{a 12, A 1 } Classical Dunnett Test A 12 := P H 0 (Z 1 d 2 interim data) Rejects H 0,1 iff q 1 A 12 A 12 > A 12 A 1 > A 12 (since d 1 < d 2 ) min{a 12, A 1 } > A 12 for all interim data (i.d.) of T 0, T 1, T 2. The adaptive Dunnett test may borrow strength from the dropped treatments to test the intersection hypotheses. Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18
23 Uniform Improvement: Conditional Error Uniform improvement after selecting only T 1 Adaptive Dunnett Test A 12 = P H0 (max(z 1, Z 2 ) d 2 i.d.) A 1 = P H0 (Z 1 d 1 interim data) Reject H 0,1 iff q 1 min{a 12, A 1 } Classical Dunnett Test A 12 := P H 0 (Z 1 d 2 interim data) Rejects H 0,1 iff q 1 A 12 A 12 > A 12 A 1 > A 12 (since d 1 < d 2 ) min{a 12, A 1 } > A 12 for all interim data (i.d.) of T 0, T 1, T 2. The adaptive Dunnett test may borrow strength from the dropped treatments to test the intersection hypotheses. Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18
24 Simulation results A Simulation Study Parallel group design with k = 2 treatments with control. Normal responses with common (known) variance (σ = 1). Testing the one sided hypotheses for the means at multiple level α = Remark for simulations Maximum sample size n for each group: such that the single stage test at the unadjusted level has power 80% at standardized treatment effect of alternative µ 1 µ 0 = 0.5 (σ = 1). interim analysis after n 1 = n/2 observations per treatment group simulation runs for each parameter combination Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18
25 Simulation results Selecting the treatment with larger effect at interim µ 2 µ 0 = 0.5 Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18
26 Simulation results Selecting the treatment with larger effect at interim µ 2 µ 0 = 0.5 Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18
27 Summary adaptive Dunnett test Adaptive Dunnett Test The Conditional error in combination with the closed test principle reduce the conservatism of the Dunnett test with treatment selection If all treatments are selected (and no other adaptations) then the adaptive Dunnett test coincides with the conventinal step down Dunnett test. One can incorporate early rejection and acceptance boundaries at interim analysis. Full flexibility Reassessment or reallocation of sample size, e.g.: reallocate the sample size of a dropped treatment equally to all treatments still under investigation. Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18
28 Simulation results: Reallocation Selecting the treatment with larger effect at interim and sample size reallocation µ 2 µ 0 = 0.5 Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18
29 Simulation results: Reallocation Selecting the treatment with larger effect at interim and sample size reallocation µ 2 µ 0 = 0.5 Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18
30 Simulation results: Reallocation Selecting the treatment with larger effect at interim and sample size reallocation µ 2 µ 0 = 0.5 Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18
31 Conlusion Conclusion: Adaptive Dunnett Test Take Home Message Start with a Dunnett Test For full flexiblity: conditional error together with the closed test Properties In principle, after every observation adaptations can be performed The interim analysis need not to be preplanned. The adaptation rules need to to be prefixed. The multiple type I error rate is controlled. Back to Reality Nobody in a clinical trial realistically would calculate the conditional error rate after every observation. However, the general principle show that an interim analysis can be performed whenever it seems appropriate without any preplanning. Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18
32 Conlusion Selected References Koenig, F., Brannath, W., Bretz, F., Bauer, P., and Posch, M. Adaptive Dunnett tests for treatment selection. Working Paper Bretz F, Schmidli H, Koenig F, Racine A, Maurer W. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: General concepts. Biometrical Journal 2006; 48(4): Hommel G. Adaptive modifications of hypotheses after an interim analysis. Biometrical Journal 2001; 43: Müller HH, Schäfer H. Adaptive group sequential designs for clinical trials: Combining the advantages of adaptive and of classical group sequential approaches. Biometrics 2001; 57: Bauer P, Kieser M. Combining different phases in the development of medical treatments within a single trial. Statistics in Medicine 1999; 18: Koenig et al (IMS) Adaptive Dunnett Tests for TS Workshop Adaptive Designs / 18
Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim
Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim Frank Bretz Statistical Methodology, Novartis Joint work with Martin Posch (Medical University
More informationAdaptive, graph based multiple testing procedures and a uniform improvement of Bonferroni type tests.
1/35 Adaptive, graph based multiple testing procedures and a uniform improvement of Bonferroni type tests. Martin Posch Center for Medical Statistics, Informatics and Intelligent Systems Medical University
More informationEstimation in Flexible Adaptive Designs
Estimation in Flexible Adaptive Designs Werner Brannath Section of Medical Statistics Core Unit for Medical Statistics and Informatics Medical University of Vienna BBS and EFSPI Scientific Seminar on Adaptive
More informationAdaptive Treatment Selection with Survival Endpoints
Adaptive Treatment Selection with Survival Endpoints Gernot Wassmer Institut für Medizinische Statisti, Informati und Epidemiologie Universität zu Köln Joint wor with Marus Roters, Omnicare Clinical Research,
More informationAdaptive clinical trials with subgroup selection
Adaptive clinical trials with subgroup selection Nigel Stallard 1, Tim Friede 2, Nick Parsons 1 1 Warwick Medical School, University of Warwick, Coventry, UK 2 University Medical Center Göttingen, Göttingen,
More informationGroup sequential designs for Clinical Trials with multiple treatment arms
Group sequential designs for Clinical Trials with multiple treatment arms Susanne Urach, Martin Posch Cologne, June 26, 2015 This project has received funding from the European Union s Seventh Framework
More informationSuperchain Procedures in Clinical Trials. George Kordzakhia FDA, CDER, Office of Biostatistics Alex Dmitrienko Quintiles Innovation
August 01, 2012 Disclaimer: This presentation reflects the views of the author and should not be construed to represent the views or policies of the U.S. Food and Drug Administration Introduction We describe
More informationFinding Critical Values with Prefixed Early. Stopping Boundaries and Controlled Type I. Error for A Two-Stage Adaptive Design
Finding Critical Values with Prefixed Early Stopping Boundaries and Controlled Type I Error for A Two-Stage Adaptive Design Jingjing Chen 1, Sanat K. Sarkar 2, and Frank Bretz 3 September 27, 2009 1 ClinForce-GSK
More informationAdaptive designs beyond p-value combination methods. Ekkehard Glimm, Novartis Pharma EAST user group meeting Basel, 31 May 2013
Adaptive designs beyond p-value combination methods Ekkehard Glimm, Novartis Pharma EAST user group meeting Basel, 31 May 2013 Outline Introduction Combination-p-value method and conditional error function
More informationAdaptive Designs: Why, How and When?
Adaptive Designs: Why, How and When? Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj ISBS Conference Shanghai, July 2008 1 Adaptive designs:
More informationMaximum type 1 error rate inflation in multiarmed clinical trials with adaptive interim sample size modifications
64 Biometrical Journal 56 24 4, 64 63 DOI:.2/bimj.2353 Maximum type error rate inflation in multiarmed clinical trials with adaptive interim sample size modifications Alexandra C. Graf,2, Peter Bauer,
More informationTesting a secondary endpoint after a group sequential test. Chris Jennison. 9th Annual Adaptive Designs in Clinical Trials
Testing a secondary endpoint after a group sequential test Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj 9th Annual Adaptive Designs in
More informationADAPTIVE SEAMLESS DESIGNS: SELECTION AND PROSPECTIVE TESTING OF HYPOTHESES
ADAPTIVE SEAMLESS DESIGNS: SELECTION AND PROSPECTIVE TESTING OF HYPOTHESES Christopher Jennison Department of Mathematical Sciences, University of Bath, Bath BA2 7AY, U. K. email: cj@maths.bath.ac.uk and
More informationComparing Adaptive Designs and the. Classical Group Sequential Approach. to Clinical Trial Design
Comparing Adaptive Designs and the Classical Group Sequential Approach to Clinical Trial Design Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj
More informationAdaptive Survival Trials
arxiv:1405.1569v1 [stat.ap] 7 May 2014 Adaptive Survival Trials Dominic Magirr 1, Thomas Jaki 2, Franz Koenig 1, and Martin Posch 1 1 Section for Medical Statistics, Medical University of Vienna, Austria
More informationAn extrapolation framework to specify requirements for drug development in children
An framework to specify requirements for drug development in children Martin Posch joint work with Gerald Hlavin Franz König Christoph Male Peter Bauer Medical University of Vienna Clinical Trials in Small
More informationclinical trials Abstract Multi-arm multi-stage (MAMS) trials can improve the efficiency of the drug
A multi-stage drop-the-losers design for multi-arm clinical trials James Wason 1, Nigel Stallard 2, Jack Bowden 1, and Christopher Jennison 3 1 MRC Biostatistics Unit, Cambridge 2 Warwick Medical School,
More informationThe Design of Group Sequential Clinical Trials that Test Multiple Endpoints
The Design of Group Sequential Clinical Trials that Test Multiple Endpoints Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj Bruce Turnbull
More informationDesigning multi-arm multi-stage clinical trials using a risk-benefit criterion for treatment selection
Research Article Statistics Received XXXX (www.interscience.wiley.com) DOI: 10.1002/sim.0000 Designing multi-arm multi-stage clinical trials using a risk-benefit criterion for treatment selection Thomas
More informationTwo-Phase, Three-Stage Adaptive Designs in Clinical Trials
Japanese Journal of Biometrics Vol. 35, No. 2, 69 93 (2014) Preliminary Report Two-Phase, Three-Stage Adaptive Designs in Clinical Trials Hiroyuki Uesaka 1, Toshihiko Morikawa 2 and Akiko Kada 3 1 The
More informationConfidence intervals and point estimates for adaptive group sequential trials
Confidence intervals and point estimates for adaptive group sequential trials Lingyun Liu, Ph.D. Cytel Inc. August 02, 2011 Miami, FL Lingyun Liu (Cytel Inc.) JSM August 02, 2011 Miami, FL 1 / 19 Acknowledgement
More informationThe Limb-Leaf Design:
The Limb-Leaf Design: A New Way to Explore the Dose Response Curve in Adaptive Seamless Phase II/III Trials John Spivack Submitted in partial fulfillment of the Requirements for the degree of Doctor of
More informationRepeated confidence intervals for adaptive group sequential trials
STATISTICS IN MEDICINE Statist. Med. 2007; 26:5422 5433 Published online 4 October 2007 in Wiley InterScience (www.interscience.wiley.com).3062 Repeated confidence intervals for adaptive group sequential
More informationCompatible simultaneous lower confidence bounds for the Holm procedure and other Bonferroni based closed tests
Compatible simultaneous lower confidence bounds for the Holm procedure and other Bonferroni based closed tests K. Strassburger 1, F. Bretz 2 1 Institute of Biometrics & Epidemiology German Diabetes Center,
More informationMULTISTAGE AND MIXTURE PARALLEL GATEKEEPING PROCEDURES IN CLINICAL TRIALS
Journal of Biopharmaceutical Statistics, 21: 726 747, 2011 Copyright Taylor & Francis Group, LLC ISSN: 1054-3406 print/1520-5711 online DOI: 10.1080/10543406.2011.551333 MULTISTAGE AND MIXTURE PARALLEL
More informationAdaptive Enrichment Designs for Randomized Trials with Delayed Endpoints, using Locally Efficient Estimators to Improve Precision
Adaptive Enrichment Designs for Randomized Trials with Delayed Endpoints, using Locally Efficient Estimators to Improve Precision MICHAEL ROSENBLUM, TIANCHEN QIAN, YU DU, and HUITONG QIU Department of
More informationMixtures of multiple testing procedures for gatekeeping applications in clinical trials
Research Article Received 29 January 2010, Accepted 26 May 2010 Published online 18 April 2011 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/sim.4008 Mixtures of multiple testing procedures
More informationPubh 8482: Sequential Analysis
Pubh 8482: Sequential Analysis Joseph S. Koopmeiners Division of Biostatistics University of Minnesota Week 10 Class Summary Last time... We began our discussion of adaptive clinical trials Specifically,
More informationOn Generalized Fixed Sequence Procedures for Controlling the FWER
Research Article Received XXXX (www.interscience.wiley.com) DOI: 10.1002/sim.0000 On Generalized Fixed Sequence Procedures for Controlling the FWER Zhiying Qiu, a Wenge Guo b and Gavin Lynch c Testing
More informationOPTIMAL, TWO STAGE, ADAPTIVE ENRICHMENT DESIGNS FOR RANDOMIZED TRIALS USING SPARSE LINEAR PROGRAMMING
Johns Hopkins University, Dept. of Biostatistics Working Papers 6-1-2017 OPTIMAL, TWO STAGE, ADAPTIVE ENRICHMENT DESIGNS FOR RANDOMIZED TRIALS USING SPARSE LINEAR PROGRAMMING Michael Rosenblum Department
More informationSequential/Adaptive Benchmarking
Sequential/Adaptive Benchmarking Manuel J. A. Eugster Institut für Statistik Ludwig-Maximiliams-Universität München Validation in Statistics and Machine Learning, 2010 1 / 22 Benchmark experiments Data
More informationPower assessment in group sequential design with multiple biomarker subgroups for multiplicity problem
Power assessment in group sequential design with multiple biomarker subgroups for multiplicity problem Lei Yang, Ph.D. Statistical Scientist, Roche (China) Holding Ltd. Aug 30 th 2018, Shanghai Jiao Tong
More informationUniversity of California, Berkeley
University of California, Berkeley U.C. Berkeley Division of Biostatistics Working Paper Series Year 2010 Paper 267 Optimizing Randomized Trial Designs to Distinguish which Subpopulations Benefit from
More informationSAMPLE SIZE RE-ESTIMATION FOR ADAPTIVE SEQUENTIAL DESIGN IN CLINICAL TRIALS
Journal of Biopharmaceutical Statistics, 18: 1184 1196, 2008 Copyright Taylor & Francis Group, LLC ISSN: 1054-3406 print/1520-5711 online DOI: 10.1080/10543400802369053 SAMPLE SIZE RE-ESTIMATION FOR ADAPTIVE
More informationUse of frequentist and Bayesian approaches for extrapolating from adult efficacy data to design and interpret confirmatory trials in children
Use of frequentist and Bayesian approaches for extrapolating from adult efficacy data to design and interpret confirmatory trials in children Lisa Hampson, Franz Koenig and Martin Posch Department of Mathematics
More informationA Type of Sample Size Planning for Mean Comparison in Clinical Trials
Journal of Data Science 13(2015), 115-126 A Type of Sample Size Planning for Mean Comparison in Clinical Trials Junfeng Liu 1 and Dipak K. Dey 2 1 GCE Solutions, Inc. 2 Department of Statistics, University
More informationAn Alpha-Exhaustive Multiple Testing Procedure
Current Research in Biostatistics Original Research Paper An Alpha-Exhaustive Multiple Testing Procedure, Mar Chang, Xuan Deng and John Balser Boston University, Boston MA, USA Veristat, Southborough MA,
More informationA Mixture Gatekeeping Procedure Based on the Hommel Test for Clinical Trial Applications
A Mixture Gatekeeping Procedure Based on the Hommel Test for Clinical Trial Applications Thomas Brechenmacher (Dainippon Sumitomo Pharma Co., Ltd.) Jane Xu (Sunovion Pharmaceuticals Inc.) Alex Dmitrienko
More informationBlinded sample size reestimation with count data
Blinded sample size reestimation with count data Tim Friede 1 and Heinz Schmidli 2 1 Universtiy Medical Center Göttingen, Germany 2 Novartis Pharma AG, Basel, Switzerland BBS Early Spring Conference 2010
More informationThe Design of a Survival Study
The Design of a Survival Study The design of survival studies are usually based on the logrank test, and sometimes assumes the exponential distribution. As in standard designs, the power depends on The
More informationCHL 5225H Advanced Statistical Methods for Clinical Trials: Multiplicity
CHL 5225H Advanced Statistical Methods for Clinical Trials: Multiplicity Prof. Kevin E. Thorpe Dept. of Public Health Sciences University of Toronto Objectives 1. Be able to distinguish among the various
More informationAlpha-recycling for the analyses of primary and secondary endpoints of. clinical trials
Alpharecycling for the analyses of primary and secondary endpoints of Presenters: clinical trials Mohammad Huque, Ph.D. FDA/CDER/OTS/ Office of Biostatistics Sirisha Mushti, Ph.D. Division of Biometrics
More informationA note on tree gatekeeping procedures in clinical trials
STATISTICS IN MEDICINE Statist. Med. 2008; 06:1 6 [Version: 2002/09/18 v1.11] A note on tree gatekeeping procedures in clinical trials Alex Dmitrienko 1, Ajit C. Tamhane 2, Lingyun Liu 2, Brian L. Wiens
More informationAre Flexible Designs Sound?
Biometrics 62, 664 683 September 2006 Are Flexible Designs Sound? Carl-Fredrik Burman and Christian Sonesson AstraZeneca R & D, SE-431 83 Mölndal, Sweden email: carl-fredrik.burman@astrazeneca.com Summary.
More informationBLINDED EVALUATIONS OF EFFECT SIZES IN CLINICAL TRIALS: COMPARISONS BETWEEN BAYESIAN AND EM ANALYSES
BLINDED EVALUATIONS OF EFFECT SIZES IN CLINICAL TRIALS: COMPARISONS BETWEEN BAYESIAN AND EM ANALYSES IBRAHIM TURKOZ, PhD Janssen Research & Development LLC, NJ BASS XX Nov, 013 BASS XX 1 Outline Introduction
More informationSample size re-estimation in clinical trials. Dealing with those unknowns. Chris Jennison. University of Kyoto, January 2018
Sample Size Re-estimation in Clinical Trials: Dealing with those unknowns Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj University of Kyoto,
More informationOriginal citation: Kimani, Peter K., Todd, Susan and Stallard, Nigel. (03) Conditionally unbiased estimation in phase II/III clinical trials with early stopping for futility. Statistics in Medicine. ISSN
More informationROI ANALYSIS OF PHARMAFMRI DATA:
ROI ANALYSIS OF PHARMAFMRI DATA: AN ADAPTIVE APPROACH FOR GLOBAL TESTING Giorgos Minas, John A.D. Aston, Thomas E. Nichols and Nigel Stallard Department of Statistics and Warwick Centre of Analytical Sciences,
More informationOptimising Group Sequential Designs. Decision Theory, Dynamic Programming. and Optimal Stopping
: Decision Theory, Dynamic Programming and Optimal Stopping Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj InSPiRe Conference on Methodology
More informationStepwise Gatekeeping Procedures in Clinical Trial Applications
984 Biometrical Journal 48 (2006) 6, 984 991 DOI: 10.1002/bimj.200610274 Stepwise Gatekeeping Procedures in Clinical Trial Applications Alex Dmitrienko *,1, Ajit C. Tamhane 2, Xin Wang 2, and Xun Chen
More informationDivision of Pharmacoepidemiology And Pharmacoeconomics Technical Report Series
Division of Pharmacoepidemiology And Pharmacoeconomics Technical Report Series Year: 2013 #006 The Expected Value of Information in Prospective Drug Safety Monitoring Jessica M. Franklin a, Amanda R. Patrick
More informationPrecision of maximum likelihood estimation in adaptive designs
Research Article Received 12 January 2015, Accepted 24 September 2015 Published online 12 October 2015 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/sim.6761 Precision of maximum likelihood
More informationGroup-Sequential Tests for One Proportion in a Fleming Design
Chapter 126 Group-Sequential Tests for One Proportion in a Fleming Design Introduction This procedure computes power and sample size for the single-arm group-sequential (multiple-stage) designs of Fleming
More informationExact Inference for Adaptive Group Sequential Designs
STATSTCS N MEDCNE Statist. Med. 2013; 00:1 [Version: 2002/09/18 v1.11] Exact nference for Adaptive Group Sequential Designs Ping Gao 1, Lingyun Liu 2, Cyrus R. Mehta 2,3 1 The Medicines Company, 2 Cytel
More informationGroup Sequential Tests for Delayed Responses. Christopher Jennison. Lisa Hampson. Workshop on Special Topics on Sequential Methodology
Group Sequential Tests for Delayed Responses Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj Lisa Hampson Department of Mathematics and Statistics,
More informationAdaptive Extensions of a Two-Stage Group Sequential Procedure for Testing a Primary and a Secondary Endpoint (II): Sample Size Re-estimation
Research Article Received XXXX (www.interscience.wiley.com) DOI: 10.100/sim.0000 Adaptive Extensions of a Two-Stage Group Sequential Procedure for Testing a Primary and a Secondary Endpoint (II): Sample
More informationGroup Sequential Designs: Theory, Computation and Optimisation
Group Sequential Designs: Theory, Computation and Optimisation Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj 8th International Conference
More informationOptimizing trial designs for targeted therapies - A decision theoretic approach comparing sponsor and public health perspectives
Optimizing trial designs for targeted therapies - A decision theoretic approach comparing sponsor and public health perspectives Thomas Ondra Sebastian Jobjörnsson Section for Medical Statistics, Medical
More informationBayesian concept for combined Phase 2a/b trials
Bayesian concept for combined Phase 2a/b trials /////////// Stefan Klein 07/12/2018 Agenda Phase 2a: PoC studies Phase 2b: dose finding studies Simulation Results / Discussion 2 /// Bayer /// Bayesian
More informationROI analysis of pharmafmri data: an adaptive approach for global testing
ROI analysis of pharmafmri data: an adaptive approach for global testing Giorgos Minas, John A.D. Aston, Thomas E. Nichols and Nigel Stallard Abstract Pharmacological fmri (pharmafmri) is a new highly
More informationTesting a Primary and a Secondary Endpoint in a Confirmatory Group Sequential Clinical Trial
Testing a Primary and a Secondary Endpoint in a Confirmatory Group Sequential Clinical Trial ExL Pharma Workshop 2010 Rockville, MD Cyrus R. Mehta President, Cytel Corporation January 26, 2010 email: mehta@cytel.com
More informationarxiv: v2 [stat.me] 24 Aug 2018
Conditional Estimation in Two-stage Adaptive Designs Per Broberg Division of Cancer Epidemiology, Department of Clinical Sciences Lund, Lund University, Skane University Hospital, Lund, Sweden. Email:
More informationA Gatekeeping Test on a Primary and a Secondary Endpoint in a Group Sequential Design with Multiple Interim Looks
A Gatekeeping Test in a Group Sequential Design 1 A Gatekeeping Test on a Primary and a Secondary Endpoint in a Group Sequential Design with Multiple Interim Looks Ajit C. Tamhane Department of Industrial
More informationAN INVESTIGATION OF TWO-STAGE TESTS. Marc Vandemeulebroecke. Otto-von-Guericke-Universität Magdeburg. and. Schering AG
AN INVESTIGATION OF TWO-STAGE TESTS Marc Vandemeulebroecke Otto-von-Guericke-Universität Magdeburg and Schering AG Abstract: Two-stage tests may be defined in terms of a combination function for the p-values
More informationPubh 8482: Sequential Analysis
Pubh 8482: Sequential Analysis Joseph S. Koopmeiners Division of Biostatistics University of Minnesota Week 12 Review So far... We have discussed the role of phase III clinical trials in drug development
More informationInterim Monitoring of Clinical Trials: Decision Theory, Dynamic Programming. and Optimal Stopping
Interim Monitoring of Clinical Trials: Decision Theory, Dynamic Programming and Optimal Stopping Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj
More informationMonitoring clinical trial outcomes with delayed response: incorporating pipeline data in group sequential designs. Christopher Jennison
Monitoring clinical trial outcomes with delayed response: incorporating pipeline data in group sequential designs Christopher Jennison Department of Mathematical Sciences, University of Bath http://people.bath.ac.uk/mascj
More informationBayesian methods for sample size determination and their use in clinical trials
Bayesian methods for sample size determination and their use in clinical trials Stefania Gubbiotti Abstract This paper deals with determination of a sample size that guarantees the success of a trial.
More informationGroup Sequential Tests for Delayed Responses
Group Sequential Tests for Delayed Responses Lisa Hampson Department of Mathematics and Statistics, Lancaster University, UK Chris Jennison Department of Mathematical Sciences, University of Bath, UK Read
More informationSome Notes on Blinded Sample Size Re-Estimation
Some Notes on Blinded Sample Size Re-Estimation arxiv:1301.4167v1 [stat.me] 17 Jan 013 Ekkehard Glimm 1 and Jürgen Läuter Abstract This note investigates a number of scenarios in which unadjusted testing
More informationOptimal exact tests for multiple binary endpoints
Optimal exact tests for multiple binary endpoints Robin Ristl 1, Dong Xi, Ekkehard Glimm 3,4, Martin Posch 1 December 3, 16 arxiv:161.7561v1 [stat.me] Dec 16 Abstract In confirmatory clinical trials with
More informationMultiple Testing in Group Sequential Clinical Trials
Multiple Testing in Group Sequential Clinical Trials Tian Zhao Supervisor: Michael Baron Department of Mathematical Sciences University of Texas at Dallas txz122@utdallas.edu 7/2/213 1 Sequential statistics
More informationUNIFORMLY MOST POWERFUL TESTS FOR SIMULTANEOUSLY DETECTING A TREATMENT EFFECT IN THE OVERALL POPULATION AND AT LEAST ONE SUBPOPULATION
UNIFORMLY MOST POWERFUL TESTS FOR SIMULTANEOUSLY DETECTING A TREATMENT EFFECT IN THE OVERALL POPULATION AND AT LEAST ONE SUBPOPULATION BY MICHAEL ROSENBLUM Department of Biostatistics, Johns Hopkins Bloomberg
More informationTwo-stage Adaptive Randomization for Delayed Response in Clinical Trials
Two-stage Adaptive Randomization for Delayed Response in Clinical Trials Guosheng Yin Department of Statistics and Actuarial Science The University of Hong Kong Joint work with J. Xu PSI and RSS Journal
More informationContrasts (in general)
10/1/015 6-09/749 Experimental Design for Behavioral and Social Sciences Contrasts (in general) Context: An ANOVA rejects the overall null hypothesis that all k means of some factor are not equal, i.e.,
More informationAn Adaptive Futility Monitoring Method with Time-Varying Conditional Power Boundary
An Adaptive Futility Monitoring Method with Time-Varying Conditional Power Boundary Ying Zhang and William R. Clarke Department of Biostatistics, University of Iowa 200 Hawkins Dr. C-22 GH, Iowa City,
More informationGroup Sequential Trial with a Biomarker Subpopulation
Group Sequential Trial with a Biomarker Subpopulation Ting-Yu (Jeff) Chen, Jing Zhao, Linda Sun and Keaven Anderson ASA Biopharm Workshop, Sep 13th. 2018 1 Outline Motivation: Phase III PD-L1/PD-1 Monotherapy
More informationBonferroni - based gatekeeping procedure with retesting option
Bonferroni - based gatekeeping procedure with retesting option Zhiying Qiu Biostatistics and Programming, Sanofi Bridgewater, NJ 08807, U.S.A. Wenge Guo Department of Mathematical Sciences New Jersey Institute
More informationTwo-Stage Sequential Designs Regulatory Perspective
Wikimedia Commons 2007 Sokoljan Creative Commons SA 3.0 Unported Two-Stage Sequential Designs Regulatory Perspective Helmut Schütz BA/BE Workshop Prague, 22 September 2016 1 Disclaimer I am not a regulator.
More informationOn the efficiency of two-stage adaptive designs
On the efficiency of two-stage adaptive designs Björn Bornkamp (Novartis Pharma AG) Based on: Dette, H., Bornkamp, B. and Bretz F. (2010): On the efficiency of adaptive designs www.statistik.tu-dortmund.de/sfb823-dp2010.html
More informationReports of the Institute of Biostatistics
Reports of the Institute of Biostatistics No 01 / 2010 Leibniz University of Hannover Natural Sciences Faculty Titel: Multiple contrast tests for multiple endpoints Author: Mario Hasler 1 1 Lehrfach Variationsstatistik,
More informationCitation for final published version: Publishers page:
This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: http://orca.cf.ac.uk/110115/ This is the author s version of a work that was submitted to / accepted
More informationControlling the False Discovery Rate in Two-Stage. Combination Tests for Multiple Endpoints
Controlling the False Discovery Rate in Two-Stage Combination Tests for Multiple ndpoints Sanat K. Sarkar, Jingjing Chen and Wenge Guo May 29, 2011 Sanat K. Sarkar is Professor and Senior Research Fellow,
More information2015 Duke-Industry Statistics Symposium. Sample Size Determination for a Three-arm Equivalence Trial of Poisson and Negative Binomial Data
2015 Duke-Industry Statistics Symposium Sample Size Determination for a Three-arm Equivalence Trial of Poisson and Negative Binomial Data Victoria Chang Senior Statistician Biometrics and Data Management
More informationInverse Sampling for McNemar s Test
International Journal of Statistics and Probability; Vol. 6, No. 1; January 27 ISSN 1927-7032 E-ISSN 1927-7040 Published by Canadian Center of Science and Education Inverse Sampling for McNemar s Test
More informationOverrunning in Clinical Trials: a Methodological Review
Overrunning in Clinical Trials: a Methodological Review Dario Gregori Unit of Biostatistics, Epidemiology and Public Health Department of Cardiac, Thoracic and Vascular Sciences dario.gregori@unipd.it
More informationFamilywise Error Rate Controlling Procedures for Discrete Data
Familywise Error Rate Controlling Procedures for Discrete Data arxiv:1711.08147v1 [stat.me] 22 Nov 2017 Yalin Zhu Center for Mathematical Sciences, Merck & Co., Inc., West Point, PA, U.S.A. Wenge Guo Department
More informationSample Size and Power I: Binary Outcomes. James Ware, PhD Harvard School of Public Health Boston, MA
Sample Size and Power I: Binary Outcomes James Ware, PhD Harvard School of Public Health Boston, MA Sample Size and Power Principles: Sample size calculations are an essential part of study design Consider
More informationMonitoring clinical trial outcomes with delayed response: Incorporating pipeline data in group sequential and adaptive designs. Christopher Jennison
Monitoring clinical trial outcomes with delayed response: Incorporating pipeline data in group sequential and adaptive designs Christopher Jennison Department of Mathematical Sciences, University of Bath,
More informationThe International Journal of Biostatistics
The International Journal of Biostatistics Volume 7, Issue 1 2011 Article 12 Consonance and the Closure Method in Multiple Testing Joseph P. Romano, Stanford University Azeem Shaikh, University of Chicago
More informationarxiv: v1 [stat.me] 24 Jul 2013
arxiv:1307.6275v1 [stat.me] 24 Jul 2013 A Two-Stage, Phase II Clinical Trial Design with Nested Criteria for Early Stopping and Efficacy Daniel Zelterman Department of Biostatistics School of Epidemiology
More informationApproaches to sample size calculation for clinical trials in small populations
Approaches to sample size calculation for clinical trials in small populations Frank Miller, Statistiska institutionen, Stockholms universitet Stockholm, 24 februari 2016 Joint work This talk is based
More informationPractical issues related to the use of biomarkers in a seamless Phase II/III design
Practical issues related to the use of biomarkers in a seamless Phase II/III design Tomasz Burzykowski International Drug Development Institute Louvain-la-Neuve, Belgium tomasz.burzykowski@iddi.be www.iddi.com
More informationReports of the Institute of Biostatistics
Reports of the Institute of Biostatistics No 02 / 2008 Leibniz University of Hannover Natural Sciences Faculty Title: Properties of confidence intervals for the comparison of small binomial proportions
More informationGroup sequential designs for negative binomial outcomes
Group sequential designs for negative binomial outcomes Tobias Mütze a, Ekkehard Glimm b,c, Heinz Schmidli b, and Tim Friede a,d a Department of Medical Statistics, University Medical Center Göttingen,
More informationSimultaneous Confidence Intervals and Multiple Contrast Tests
Simultaneous Confidence Intervals and Multiple Contrast Tests Edgar Brunner Abteilung Medizinische Statistik Universität Göttingen 1 Contents Parametric Methods Motivating Example SCI Method Analysis of
More informationTesting hypotheses in order
Biometrika (2008), 95, 1,pp. 248 252 C 2008 Biometrika Trust Printed in Great Britain doi: 10.1093/biomet/asm085 Advance Access publication 24 January 2008 Testing hypotheses in order BY PAUL R. ROSENBAUM
More informationGroup sequential designs with negative binomial data
Group sequential designs with negative binomial data Ekkehard Glimm 1 Tobias Mütze 2,3 1 Statistical Methodology, Novartis, Basel, Switzerland 2 Department of Medical Statistics, University Medical Center
More informationImpact of covariate misclassification on the power and type I error in clinical trials using covariate-adaptive randomization
Impact of covariate misclassification on the power and type I error in clinical trials using covariate-adaptive randomization L I Q I O N G F A N S H A R O N D. Y E A T T S W E N L E Z H A O M E D I C
More informationOptimal group sequential designs for simultaneous testing of superiority and non-inferiority
Optimal group sequential designs for simultaneous testing of superiority and non-inferiority Fredrik Öhrn AstraZeneca R & D Mölndal, SE-431 83 Mölndal, Sweden and Christopher Jennison Department of Mathematical
More information